Vanda Pharmaceuticals (VNDA) Net Income Growth (5y) (2015 - 2026)

Vanda Pharmaceuticals (VNDA) Net Income Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Vanda Pharmaceuticals 310.98 Mn 108.67 Mn 48.56 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -50.06%
Dec 31, 2025 -80.59%
Sep 30, 2025 -42.12%
Jun 30, 2025 -38.68%
Mar 31, 2025 -128.79%
Dec 31, 2024 -25.81%
Sep 30, 2024 -15.47%
Jun 30, 2024 -19.06%
Mar 31, 2024 -46.61%
Dec 31, 2023 -17.40%
Sep 30, 2023 -54.69%
Jun 30, 2023 -20.20%
Mar 31, 2023 1.04%
Dec 31, 2022 41.80%
Sep 30, 2022 22.13%
Jun 30, 2022 29.83%
Mar 31, 2022 3.30%
Dec 31, 2021 74.45%
Sep 30, 2021 81.98%
Jun 30, 2021 32.54%